ETV4 (E1W1G) Rabbit mAb #65763
- WB
- IP
- ChIP
- C&R
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 54-61 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- ChIP-Chromatin Immunoprecipitation
- C&R-CUT & RUN
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
The CUT&RUN dilution was determined using CUT&RUN Assay Kit #86652.
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
| Chromatin IP | 1:200 |
| CUT&RUN | 1:100 |
Storage
Protocol
Specificity / Sensitivity
ETV4 (E1W1G) Rabbit mAb recognizes endogenous levels of total ETV4 protein. This antibody does not cross-react with ETV5 protein, and based on observed expression is not predicted to cross-react with ETV1 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant protein fragment specific to human ETV4 protein.
Background
ETS translocation variant 4 (ETV4, PEA3, E1AF) is a member of the PEA3 (polyomavirus enhancer activator 3) subfamily of the E26 transformation-specific (ETS) DNA-binding transcription factors, which commonly bind a core DNA sequence of 5'-GGA(A/T)-3' (1,2). The PEA3 subfamily of ETV1, ETV4, and ETV5 are considered oncogenic transcription factors due to their overexpression and promotion of tumorigenesis in numerous cancers (2,3). ETV4 can be activated via the RAS-RAF-MEK-ERK pathway (2,4) or the PI3K/Akt pathway (5), and loss-of-function mutations of PEA3-family repressors such as CIC can increase ETV4 expression independent of either pathway (2,6). Though rare, 5' chromosomal fusions to ETV4 are drivers of metastasis in prostate cancer (7) and Ewing sarcoma (8). ETV4 regulates the expression of genes that control several developmental processes, including cell growth, differentiation, proliferation, survival, and cell cycle progression (9-11).
- Oh, S. et al. (2012) Biochim Biophys Acta 1826, 1-12.
- Qi, T. et al. (2020) Am J Cancer Res 10, 3083-3105.
- Jiang, W. et al. (2021) Mol Ther Oncolytics 22, 518-527.
- DeSalvo, J. et al. (2021) J Clin Invest 131, e141908. doi: 10.1172/JCI141908.
- Wang, J. et al. (2022) Oncol Lett 23, 41.
- Hung, Y.P. et al. (2016) Mod Pathol 29, 1324-1334.
- Tomlins, S.A. et al. (2006) Cancer Res 66, 3396-400.
- Boone, M.A. et al. (2021) Mol Cancer Res 19, 1795-1801.
- Xu, L. et al. (2020) Cancer Lett 482, 74-89.
- Yao, D. et al. (2021) Cell Biol Int 45, 2129-2139.
- Tyagi, N. et al. (2018) Mol Cancer Res 16, 187-196.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.